Gastric Carcinoma — Trials

Gastric Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

586 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 183
Recruiting: 93
Ph III recruiting: 15
Growth YoY: +4.3%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (65)

clinicaltrialsPublishedShowing 1–22 of 22 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06203600	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	recruiting	Phase 2 / Phase 3	224	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT07315750	A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.	recruiting	Phase 3	555	RemeGen Co., Ltd.INDUSTRY	1	Sep 22, 2026